Therapeutics News

NEW YORK – Four panelists shared differing treatment strategies when using steroids, Restasis and Xiidra for dry eye.

AXIM Biotechnologies Inc. announced it has retained the services of Ora Inc. to perform the company’s upcoming product development and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics.

ATLANTA – Here at SECO during a Primary Care Optometry News-sponsored course on therapeutics, Carl Spear, OD, said he treats herpes simplex keratitis by first performing débridement to interrupt the viral replication and prevent a future stromal episode.

ATLANTA – Eric Sigler, MD, focused on choroidal retinal degenerations during the Retina Roundup here at SECO. “We found that it’s an exciting time, as many treatments will be effective in the future like lampalizumab and other genetic therapies to modify the risk and progression of macular degeneration,” he said.

Each room in my clinic has a list of medications taped to the wall. It’s basically the only thing on the walls besides the phone number to call during an emergency and the eye chart.

Let’s say you’re going to the hardware store to buy a wrench. Naturally, the store sells more than one product that can do the same job, but let’s pretend that one wrench is, say, 10% better than another. Maybe it requires 10% less effort to turn the bolt or maybe it turns the bolt 10% tighter. How much more would you pay for that wrench?

Nicox is finalizing the design of a first-in-human trial for NCX 470, its novel nitric oxide donating bimatoprost analog being developed for intraocular pressure lowering, according to a press release.

Fixed combination travoprost 0.004%-timolol 0.5% may promote improved adherence compared with separate containers of travoprost 0.004% and timolol 0.5% in patients with glaucoma or ocular hypertension who require multi-agent therapy, according to researchers in the American Journal of Ophthalmology.

After a positive recommendation from the European Medicines Agency, the European Commission has granted orphan drug designation to BB-301, an investigational therapy for the treatment of ocularpharyngeal muscular dystrophy, the manufacturer announced.

In the mid-1990s, the FDA relaxed regulations regarding direct-to-consumer pharmaceutical advertising that brought ads for medications from the magazine pages (where they were heavily advertised with lots of small print) to the television airwaves.